Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CytoDyn Inc. (CYDY : OTC)

• Company Description    CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of HIV infection. The Company has one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which has completed Phase 2 clinical trials with demonstrated antiviral activity in humans and is currently in Phase 3 development. PRO 140 blocks the HIV co-receptor CCR5 on T cells, which prevents viral entry. Clinical trial results thus far indicate that PRO 140 does not negatively affect the normal immune functions that are mediated by CCR5. Results from seven Phase 1 and Phase 2 human clinical trials have shown that PRO 140 can significantly reduce viral burden in people infected with HIV. A recent Phase 2b clinical trial demonstrated that PRO 140 can prevent viral escape in patients during several months of interruption from conventional drug therapy. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $0.32 Daily Weekly Monthly 20 Day Moving Average: 1,481,894 shares Shares Outstanding: 1,251.53 (millions) Market Capitalization: $398.24 (millions) Beta: 1.17 52 Week High: $0.49 52 Week Low: $0.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -10.49% -13.84% 12 Week 55.98% 31.20% Year To Date 190.06% 171.64%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1111 MAIN STREET SUITE 660 - VANCOUVER,WA 98660 USA ph: 360-980-8524 fax: - mciszewski@cytodyn.com http://www.cytodyn.com

• General Corporate Information    Officers Jacob Lalezari - Chief Executive Officer Tanya Durkee Urbach - Chairman Mitchell Cohen - Chief Financial Officer Karen J. Brunke - Director Ryan M. Dunlap - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 23283M101 SIC: 2834 Fiscal Year Fiscal Year End: May Last Reported Quarter: 02/01/25 Next Expected EPS Date: 08/21/25 Share - Related Items Shares Outstanding: 1,251.53 Most Recent Split Date: (:1) Beta: 1.17 Market Capitalization: $398.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/21/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 100.00% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 05/31/25 - - 02/28/25 - - 11/30/24 - - ROA 05/31/25 - - 02/28/25 - -33.26 11/30/24 - -76.70 Current Ratio 05/31/25 - - 02/28/25 - 0.30 11/30/24 - 0.35 Quick Ratio 05/31/25 - - 02/28/25 - 0.30 11/30/24 - 0.35 Operating Margin 05/31/25 - - 02/28/25 - - 11/30/24 - - Net Margin 05/31/25 - - 02/28/25 - - 11/30/24 - - Pre-Tax Margin 05/31/25 - - 02/28/25 - - 11/30/24 - - Book Value 05/31/25 - - 02/28/25 - -0.08 11/30/24 - -0.07 Inventory Turnover 05/31/25 - - 02/28/25 - - 11/30/24 - - Debt-to-Equity 05/31/25 - - 02/28/25 - - 11/30/24 - - Debt-to-Capital 05/31/25 - - 02/28/25 - - 11/30/24 - -

Powered by Zacks Investment Research ©